Amgen amend GDNF gene permit agreement Amsterdam Molecular Therapeutics Holding N.

The voucher was awarded by the FDA under a provision that encourages advancement of new medications and biologics for the avoidance and treatment of uncommon pediatric diseases. We are very very happy to monetize our PPRV, and hope that this transaction will encourage others to join us in focusing advancement efforts on rare pediatric diseases, stated Roger Jeffs, Ph.D., United Therapeutics' Co-CEO and President. The transaction is at the mercy of customary closing circumstances and clearance beneath the Hart-Scott-Rodino Antitrust Improvements Action.. AMT, Amgen amend GDNF gene permit agreement Amsterdam Molecular Therapeutics Holding N.V. , a innovator in the advancement of gene-centered therapies, today announced that it provides amended and restated its licensing contract with Amgen for gene therapy applications incorporating the GDNF gene, to which Amgen keeps rights.New Antibiotic-Resistant ‘Superbug’ an Emerging Danger, CDC Says: – MONDAY, Oct. 5, 2015 – – A relatively new antibiotic-resistant bacterias called CRE is making inroads in some major American metropolitan areas, U.S. Wellness officials report. Surveillance of seven U.S. Metropolitan areas found higher-than-expected degrees of CRE in Atlanta, Baltimore and New York City, according to the U.S. Centers for Disease Avoidance and Control. Lower-than-expected levels were found in Albuquerque, Denver and Portland, Ore., as the Minneapolis rate was what the agency anticipated. But CDC researchers were dismayed that they found active cases of CRE infection in every populous city they examined, said senior author Dr.